Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME

Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.

Subodh Verma¹, C David Mazer², Mohammed Al-Omran^{3

4}, Silvio E Inzucchi⁵, David Fitchett⁶, Uwe Hehnke⁷, Jyothis T George⁷, Bernard Zinman^{8

9}

¹ St. Michael's Hospital, Division of Cardiac Surgery (S.V.) vermasu@smh.ca.
² Department of Anesthesia (C.D.M.).
³ Division of Vascular Surgery (M.A.-O.).
⁴ Department of Surgery, King Saud University, Riyadh, Saudi Arabia (M.A.-O.).
⁵ Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.).
⁶ Division of Cardiology (D.F.), University of Toronto, Ontario, Canada.
⁷ Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (U.H., J.T.G.).
⁸ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada (B.Z.).
⁹ Division of Endocrinology, University of Toronto, Ontario, Canada (B.Z.).

No abstract available

Keywords: diabetes mellitus peripheral arterial disease; sodium-glucose cotransporter 2.

Publication types